EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY 4.0

Safety and Efficacy of Levomilnacipran Extended Release in Pediatric Patients Aged 7–17 Years with Major Depressive Disorder: Results of Two Phase 3, Randomized, Double-Blind Studies

Daniel T Radecki, Weining Z Robieson, Mallika Gopalkrishnan, Edward Greenberg, Mohamed Aziz iD

Journal of Child and Adolescent Psychopharmacology · 2024

DOI: 10.1089/cap.2023.0080 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Child and Adolescent Psychopharmacology, 2024. Verfasst von Daniel T Radecki und 4 weiteren Autor:innen. Beteiligte Einrichtung: AbbVie, Irvine, California, USA. Hauptthemen laut MEDLINE: Major Depressive Disorder, Milnacipran, Fluoxetine, Delayed-Action Preparations. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Major depressive disorder (MDD) presents a significant psychosocial burden, and there is an unmet need for additional treatment options in pediatric patients. Here, we report the results of two phase 3 multicenter, randomized, double-blind, placebo- and active-controlled, parallel-group studies evaluating the efficacy and safety of levomilnacipran extended release in children and adolescents with MDD.

Methods

In the first study, LVM-MD-11, patients aged 12–17 years received daily doses of levomilnacipran 40 mg ( n = 134), levomilnacipran 80 mg ( n = 138), fluoxetine 20 mg ( n = 134), or placebo ( n = 141). In the second study, LVM-MD-14, patients aged 7–17 years received levomilnacipran 40 to 80 mg ( n = 166), fluoxetine 20 mg ( n = 166), or placebo ( n = 160) daily. Primary and secondary efficacy endpoints were changes in Children's Depression Rating Scale-Revised (CDRS-R) total score and Clinical Global Impressions-Severity (CGI-S) score, respectively.

Results

In LVM-MD-11, there were no significant differences in change in CDRS-R total score between patients treated daily with placebo (least squares mean [LSM] change in CDRS-R total score −22.9) versus levomilnacipran 40 mg (−23.3; p = 0.8035) or 80 mg (−22.6; p = 0.8681). Similarly, in LVM-MD-14, there were no significant differences in LSM change in CDRS-R total score with placebo (−21.3) versus levomilnacipran 40 to 80 mg daily (−23.0; p = 0.2215). There were also no significant differences between the fluoxetine and placebo groups in either study for changes in CDRS-R total score. Changes in CGI-S score were not significant between placebo and levomilnacipran 40 to 80 mg daily or between placebo and fluoxetine. Levomilnacipran was generally well tolerated.

Conclusions

The high placebo response in this study prevented the detection of an effect of levomilnacipran in children and adolescents. Clinical Trial Registration numbers: NCT02431806 and NCT03569475.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Major Depressive DisorderMilnacipranFluoxetineDelayed-Action PreparationsHumansChildAdolescentDouble-Blind MethodFemaleMaleTreatment OutcomeSelective Serotonin Reuptake InhibitorsDose-Response Relationship, DrugPsychiatric Status Rating ScalesAntidepressive Agents

Stichwörter der Autor:innen

antidepressantslevomilnacipranmajor depressive disorderpediatric

Substanzen

MilnacipranFluoxetineDelayed-Action PreparationsSelective Serotonin Reuptake InhibitorsAntidepressive Agents

Autor:innen und Institutionen

  • AbbVie, Irvine, California, USA.
  • AbbVie, North Chicago, Illinois, USA.
  • AbbVie, Madison, New Jersey, USA.
  • AbbVie, Lake Bluff, Illinois, USA.
  • Professional Psychiatric Services, Cincinnati, Ohio, USA.

ORCID-Profile: Mohamed Aziz

Zitieren

APA

Radecki, D. T., Robieson, W. Z., Gopalkrishnan, M., Greenberg, E., & Aziz, M. (2024). Safety and Efficacy of Levomilnacipran Extended Release in Pediatric Patients Aged 7–17 Years with Major Depressive Disorder: Results of Two Phase 3, Randomized, Double-Blind Studies. Journal of Child and Adolescent Psychopharmacology. https://doi.org/10.1089/cap.2023.0080

Vancouver

Radecki DT, Robieson WZ, Gopalkrishnan M, Greenberg E, Aziz M. Safety and Efficacy of Levomilnacipran Extended Release in Pediatric Patients Aged 7–17 Years with Major Depressive Disorder: Results of Two Phase 3, Randomized, Double-Blind Studies. Journal of Child and Adolescent Psychopharmacology. 2024. doi:10.1089/cap.2023.0080

BibTeX
@article{Radecki2024,
  author = {Radecki, Daniel T and Robieson, Weining Z and Gopalkrishnan, Mallika and Greenberg, Edward and Aziz, Mohamed},
  title = {Safety and Efficacy of Levomilnacipran Extended Release in Pediatric Patients Aged 7–17 Years with Major Depressive Disorder: Results of Two Phase 3, Randomized, Double-Blind Studies},
  journal = {Journal of Child and Adolescent Psychopharmacology},
  year = {2024},
  doi = {10.1089/cap.2023.0080}
}
Kostenlos starten →